WATD and Cancer-Related Fatigue: A Study For Patients Undergoing Anti-Cancer Treatment

Inclusion Criteria:

• Written informed consent and HIPAA authorization for release of personal healthinformation

• Patients pancreatic or invasive breast cancer per enrolling investigator who isplanning on or has started anti-cancer treatment. Note: Patients with cancer who arenot planning to receive anti-cancer treatment are not eligible for studyparticipation

• Patients with any severity of self-reported fatigue per enrolling investigator

• Age ≥ 18 years at the time of consent

• Ability to read and understand the English language

• As determined by the enrolling investigator, the ability of the participant tounderstand and comply with study procedures (i.e., completing questionnaires anddevice return) for the entire length of the study

Exclusion Criteria:

• Any documented, clinically significant cardiac-related abnormality per enrollinginvestigator that could compromise the outcome of the study. NOTE: The heart ratedata collected using the WATD will not be used for patient care.

• Other factors or conditions, per investigator discretion, for which participation inthe study would not be in the patient's best interest or could interfere with studyassessment results or preclude study completion

• No internet, Wi-Fi access or email account

• No access to a smartphone or mobile device